Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 04'th Nov 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022
12:00pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
09:25pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
11:28am, Monday, 24'th Oct 2022 Benzinga
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Pearson plc (NYSE: PSO) shares gained 7.7% to $10.73 in pre-market tra
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?
01:40pm, Monday, 17'th Oct 2022 Zacks Investment Research
Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.
Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer
08:05pm, Thursday, 06'th Oct 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Tuesday, 04'th Oct 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies
12:02pm, Friday, 30'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, today announced the launch of Oncology FACETS: an educatio
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 02'nd Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?
01:55pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
09:27am, Monday, 15'th Aug 2022
Shares of Mersana Therapeutics are up 21% in 2022 and +168% over the past 3 years. Management sees lead antibody drug conjugate UpRi gaining broad use in ovarian cancer, though I remain skeptical.
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
10:05am, Friday, 12'th Aug 2022 Zacks Investment Research
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
03:25pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
07:52am, Wednesday, 10'th Aug 2022 Benzinga
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
BBQ Holdings, Inc. (NAS
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
05:26pm, Tuesday, 09'th Aug 2022 Benzinga
Gainers
Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for CO
